Clinical Trial Update: Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating VERU-111 for metastatic castration-resistant prostate cancer after AR-targeting therapy has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Androgen Resistant Prostatic Cancer
• Castration-resistant Prostate Cancer

Drugs mentioned

• VERU-111 (VERU-111)

Snippet

Sponsor: Veru Inc. | Conditions: Metastatic Castration-resistant Prostate Cancer, Androgen Resistant Prostatic Cancer | Phase 3 | Status: TERMINATED